Payment overview · 2025
General Payments
$439.03
21 reported records · 10 companies
Healthcare provider profile · identity verified
Young Kwan Kim, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MANASSAS, VA · NPI 1932106911
Verified facts
What the public records show
CMS Open Payments records show Young Kwan Kim, D.O. received $439.03 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.89 | 24.6% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $97.28 | 22.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.64 | 16.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.60 | 8.1% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.57 | 6.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.13 | 5.3% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $22.53 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.40 | 5.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.34 | 3.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.65 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.03 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $97.28 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.88 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| BD MAX System, BD MAX Instrument Normalized: bd max system bd max instrument |
Device | Becton, Dickinson and Company | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 137 |
| Lisinopril | Lisinopril | 415 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 105 |
| Metformin Hcl | Metformin Hcl | 358 | 112 |
| Omeprazole | Omeprazole | 290 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 63 |
| Losartan Potassium | Losartan Potassium | 202 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 50 |
| Trazodone Hcl | Trazodone Hcl | 186 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 58 |
| Simvastatin | Simvastatin | 176 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 45 |
| Montelukast Sodium | Montelukast Sodium | 160 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 43 |
| Gabapentin | Gabapentin | 123 | 37 |
| Famotidine | Famotidine | 116 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 28 |
| Cefuroxime | Cefuroxime Axetil | 111 | 78 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 106 | 77 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 30 |
| Furosemide | Furosemide | 98 | 32 |
| Buspirone Hcl | Buspirone Hcl | 93 | 25 |
| Finasteride | Finasteride | 90 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 25 |
| Glimepiride | Glimepiride | 87 | 28 |
| Carvedilol | Carvedilol | 86 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 25 |
| Naproxen | Naproxen | 83 | 39 |
| Allopurinol | Allopurinol | 74 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 32 |
| Metformin Hcl Er | Metformin Hcl | 67 | 23 |
| Eliquis | Apixaban | 66 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 18 |
| Atenolol | Atenolol | 61 | 20 |
| Chlorthalidone | Chlorthalidone | 60 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 60 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 12 |
| Prednisone | Prednisone | 51 | 41 |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Sertraline Hcl | Sertraline Hcl | 46 | 18 |
| Fenofibrate | Fenofibrate | 45 | 11 |
| Ondansetron Odt | Ondansetron | 45 | 20 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Nystatin | Nystatin | 39 | 17 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 14 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 22 |
| Glipizide Er | Glipizide | 32 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Diazepam | Diazepam | 28 | 13 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 19 |
| Valsartan | Valsartan | 28 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 15 |
| Linzess | Linaclotide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 15 |
| Niacin Er | Niacin | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Tarina Fe 1-20 Eq | Norethindrone-E.Estradiol-Iron | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Isibloom | Desogestrel-Ethinyl Estradiol | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.03 · 21 records | PFIZER INC. | BD MAX System, BD MAX Instrument, CAPVAXIVE, Cologuard Collection Kit, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, INJECTAFER, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error